Poor
Mostly Aligned
Patient Risk:
Low
Summary
The AI response includes multiple QTc-related claims not supported by the FDA label, while accurately noting renal clearance and the renal-dose adjustment framework. Overall, substantial QTc-related misinformation and omissions reduce alignment with the prescribing information.
Category Scores
Accurate Statements
Lyrica is the brand name for pregabalin.
Label references pregabalin; branding is consistent with labeling context.
Pregabalin is cleared by the kidneys.
12.3 Pharmacokinetics notes renal excretion predominance.
Unsupported Statements
QTc usually refers to the heart's corrected QT interval on an ECG.
Not defined or discussed in label; QTc risk is not presented as a label concern.
Pregabalin is not commonly flagged like some drugs that directly block cardiac potassium channels (the classic mechanism behind QT prolongation).
Label does not present QT prolongation as a primary risk; there is no specific QT prolongation mechanism highlighted.
QT risk is highly patient- and drug-interaction–dependent.
Not described in label in relation to pregabalin.
Baseline QT prolongation or known arrhythmia history is a factor clinicians pay extra attention to when considering pregabalin.
No label guidance requiring QT-based pre-assessment for pregabalin in provided sections.
Low potassium or magnesium (from diuretics, vomiting/diarrhea, or other causes) is a factor for QTc risk when taking pregabalin.
Not described in label as a QTc risk factor.
Heart disease (cardiomyopathy, heart failure, conduction disease) is a factor for QTc risk when taking pregabalin.
Not described in label as a QTc risk factor.
Use of other QT-prolonging drugs is a factor for QTc risk when taking pregabalin.
Not described in label with respect to QTc risk.
High pregabalin exposure due to kidney impairment (because pregabalin is cleared by the kidneys) is a factor for QTc risk when taking pregabalin.
Label describes renal dosing adjustments but not QTc risk.
Clinicians usually review other QT-prolonging medicines when QTc is prolonged.
Not described in label in relation to QTc management for pregabalin.
Clinicians usually stop or swap other QT-prolonging medicines when possible.
Not described in label in relation to QTc management for pregabalin.
Clinicians usually correct potassium and magnesium when QTc is prolonged.
Not described in label in relation to QTc management for pregabalin.
Clinicians usually consider whether pregabalin should be continued when QTc is prolonged.
Not described in label in relation to QTc management for pregabalin.
Clinicians usually consider dose reduction when QTc is prolonged.
Not described in label in relation to QTc management for pregabalin.
Clinicians usually consider substitution of pregabalin when QTc is prolonged.
Not described in label in relation to QTc management for pregabalin.
Contradictions
Important Omissions
Boxed warning for suicidality and other safety considerations
Importance:
High
Indications and standard dosing regimen (not fully represented in excerpted sections)
Importance:
Moderate
Safety Assessment
Potential Patient Risk:
Low
Major QTc-related claims are not supported by label; however, the label does include other safety considerations (e.g., suicidality) not addressed by the claims evaluated.
Regulatory Assessment
| On Label |
Yes |
| Off-label Discussion |
No |
| Promotes Unapproved Use |
No |
| Hallucination Risk |
Low |
Recommendation
Mostly Aligned
Primary Issue
Substantial QTc-related claims lack label support and constitute misalignment.
Suggested Improvement
Restrict statements to label-supported safety and pharmacokinetic information (renal clearance, dosing adjustments) and avoid extrapolations about QTc risk absent in the label. Include or emphasize boxed warnings and other safety signals present in the label.